Predictions
Biogen Inc.
Start price
Target price
Perf. (%)
€205.20
12.05.24
12.05.24
€207.00
12.05.25
12.05.25
3.85%
06.06.24
06.06.24
Good rating
Standard Investments for future growth
Innovative
Differentiated customer and product portfolio
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€307.95
30.05.23
30.05.23
€356.18
30.05.24
30.05.24
33.25%
31.05.24
31.05.24
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€397.00
24.05.23
24.05.23
€464.75
24.05.24
24.05.24
88.34%
25.05.24
25.05.24
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€397.00
24.05.23
24.05.23
€462.89
24.05.24
24.05.24
88.34%
25.05.24
25.05.24
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€403.60
14.05.23
14.05.23
€700.00
14.05.24
14.05.24
76.01%
15.05.24
15.05.24
Could be worthwhile Investment >10% per year
Biogen Inc.
Start price
Target price
Perf. (%)
€194.35
27.04.24
27.04.24
€200.00
27.04.25
27.04.25
5.58%
12.05.24
12.05.24
Good rating
Standard Investments for future growth
Innovative
Differentiated customer and product portfolio
Merck & Co. Inc.
Start price
Target price
Perf. (%)
€103.40
11.04.23
11.04.23
€113.61
11.04.24
11.04.24
13.73%
12.04.24
12.04.24
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€736.80
23.03.23
23.03.23
€791.57
23.03.24
23.03.24
20.86%
24.03.24
24.03.24
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€307.70
13.03.23
13.03.23
€350.10
13.03.24
13.03.24
124.73%
14.03.24
14.03.24
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€299.80
03.03.23
03.03.23
€339.30
03.03.24
03.03.24
142.83%
04.03.24
04.03.24
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€529.00
18.12.23
18.12.23
€558.00
18.12.24
18.12.24
6.62%
06.01.24
06.01.24
Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€239.95
01.04.22
01.04.22
€330.00
18.12.23
18.12.23
41.68%
14.11.23
14.11.23
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€337.60
09.04.23
09.04.23
€362.00
09.10.23
09.10.23
57.73%
09.10.23
09.10.23
Amgen Inc.
Start price
Target price
Perf. (%)
€246.80
19.09.23
19.09.23
€250.00
19.09.24
19.09.24
4.13%
27.09.23
27.09.23
Could be worthwhile Investment >10% per year
High dividend yield expected
positive Cash Flow expected
Good rating
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€502.50
17.08.23
17.08.23
€510.00
17.08.24
17.08.24
10.75%
13.09.23
13.09.23
Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
Johnson & Johnson
Start price
Target price
Perf. (%)
€152.60
24.07.23
24.07.23
€155.00
24.07.24
24.07.24
3.47%
16.08.23
16.08.23
High dividend yield expected
positive Cash Flow expected
Good rating
Standard Investments for future growth
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€388.00
05.05.23
05.05.23
€395.00
05.05.24
05.05.24
3.52%
12.05.23
12.05.23
Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
Biogen Inc.
Start price
Target price
Perf. (%)
€208.25
27.12.21
27.12.21
€215.00
27.12.22
27.12.22
23.82%
28.12.22
28.12.22
Could be worthwhile Investment >10% per year
Johnson & Johnson
Start price
Target price
Perf. (%)
€140.70
27.11.21
27.11.21
€160.00
27.11.22
27.11.22
21.35%
28.11.22
28.11.22
Could be worthwhile Investment >10% per year
Significant cyclical dependencies
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€533.60
09.11.21
09.11.21
€600.00
09.11.22
09.11.22
38.91%
10.11.22
10.11.22
Could be worthwhile Investment >10% per year
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€338.70
07.10.22
07.10.22
€350.00
07.10.23
07.10.23
7.12%
29.10.22
29.10.22
Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€59.87
15.05.22
15.05.22
€68.00
15.05.23
15.05.23
32.12%
28.10.22
28.10.22
Could be worthwhile Investment >10% per year
positive Cash Flow expected
ROE higher than 15% per year
Normal challenges to pay loans and raise capital